The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

Treating IBD with Anti-TNF Tied to Higher Risk of Demyelinating Disease

October 9, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors is associated with a doubling of the risk of central nervous system demyelinating disease, researchers from Denmark report.

You Might Also Like
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment
  • Skin Complications of Anti-TNF Therapy Common in IBD

“Based on the current evidence anti-TNF should be used cautiously in patients with an own or family history of demyelinating disease,” Dr. Nynne Nyboe Andersen from Statens Serum Institut in Copenhagen told Reuters Health by email.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Patients treated with anti-TNF should be closely monitored for demyelinating disease with neurological examinations and if a patient develops signs of demyelinating during ongoing treatment, therapy should be discontinued promptly,” Dr. Andersen said.

“Previous case reports, retrospective cohort studies, and data from spontaneous surveillance reporting systems have identified patients treated with anti-TNF developing a demyelinating event, such as multiple sclerosis and optic neuritis,” Dr. Andersen noted. “It remains uncertain, however, whether these demyelinating events reflect a coincidental event or whether they are causally associated with anti-TNF.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Andersen and colleagues used data from the Danish Civil Registration System to compare rates of central demyelinating diseases among 4,504 patients with IBD exposed to anti-TNF and more than 16,400 matched IBD patients without exposure to the drugs.

Exposed patients experienced 11 central demyelinating events, for a rate of 7.5 events per 10,000 person-years. By comparison, unexposed patients experienced 17 central demyelinating events, for a rate of 3.3 events per 10,000 person years.

The risk of central demyelinating disease was significantly higher among exposed than among unexposed IBD patients (hazard ratio, 2.19). But the absolute risk difference was only 3.9 events per 10,000 person years, the researchers report in JAMA Internal Medicine, online Oct. 5.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Running the analysis 10,000 times with a new random selection of controls in each analysis resulted in a median 1.95-fold risk increase among those exposed to anti-TNF agents.

“Despite bringing novel data on the relative risk of demyelinating diseases associated with TNF- inhibitors, our study findings need confirmation in even larger scale studies with increased methodological robustness and precision before any changes in therapeutic management should be made,” Dr. Andersen concluded.

 

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Anti-TNF, anti-TNF agent, central nervous system, demyelinating disease, inflammatory bowel disease

You Might Also Like:
  • IBD Tied to Higher Risk of Invasive Pneumococcal Disease
  • Increased Risk of Serious Infections During Early Anti-TNF Treatment
  • Skin Complications of Anti-TNF Therapy Common in IBD
  • Anti-TNF-Associated Skin Lesions Common in Inflammatory Bowel Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)